The comments & viewpoints are my own and are not endorsed or necessarily representative of UH CMC, CWRU, NCCN, FDA, NCI, or NRG. They are my personal opinion.
X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere.
The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc@theNCI@US_FDA and dedicated my career to help men and their families suffering from PCa
@nytimes@WSJ@FoxNews@CNN@NBCNews@Reuters@ASCO@PCFnews @DeptofDefense
I think most thoracic surgeons and thoracic oncologist would welcome an apples to apples comparison of ChemoICI-surgery vs ChemoICI-XRT
Until then, patients deserve the treatment strategy that has been shown in this patient population to have the best outcomes
When speaking with patients we must share the data we have, not the data we think might be
Everyone: “AI is advancing so fast it may soon surpass human intelligence and end the world.”
Me: Wake me when it figures out how to get 180 people onto an airplane in under 40 minutes.
If the machines can solve Zone 7 standing in the aisle while Zone 1 is still boarding, then I’ll start worrying.
I think we have some time. @Delta
A growing body of evidence suggests millions of surgeries performed each year are unnecessary. They cause needless physical pain and financial stress—and are a terrible waste of resources
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
doi.org/10.1016/j.euo.2026.0…@AmarUKishan@DrSpratticus@alison_tree
📣 When #RadOnc finds its voice! ☢️
Different institutions. Different perspectives. One community — connecting, communicating & sharing the stories and science that move our field forward 🚀
We ❤️ #radonc
We ❤️ our #patients
And yes… #WeWhoCurie 😉
@ASTRO_org@ASTRO_Chair
Bladder preservation deserves a larger place in MIBC research. More randomized trials should be built around improving trimodality therapy, systemic integration, and long-term bladder-intact survival. What should we test next? @OncoAlert@OpenMedicineHQ@Uromigos@urotoday
Another @RadOncUH PGY-4 with an 🎤🔥oral presentation today! @SamLM_MD killing it presenting the ✅feasibility of planning on HyperSight CBCT on TrueBeam in a prospective trial- @SiemensHealth Varian CMO @DrDee2014 & physics PI @APrice_BeamOn both front row, cheering him on!
NCT05975619
@RadOncUH PGY-4 @QingLi_MDPhD 🔥crushing it with an(other) 🎤oral presentation this morning on her #HolmanPathway work on how RT modulates HER2 expression and trastuzuman deruxtecan response in HER2 low metastatic breast cancer.
#bcsm@TyMillerLab
SYMPHONY (Salvage RadiotherapY Multi-arm biomarker and PSMA-guided HarmONY) -- discussed by @DrSpratticus during the #ASTRO26 Use of Novel Biomarkers in GU Cancers session
Impressive NRG led (STAMPEDE-like) platform in the approval process for answering several key questions
@urotoday
Surgery or 5 sessions of radiation? For the first time, we have randomised head-to-head efficacy data. 🔥 #PACE_A at #ASTRO26 shows comparable 8-year cancer control, and nearly half of surgical patients still use pads at 5 years.
LBA 32 - EFFICACY OF RADICAL PROSTATECTOMY VERSUS STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR LOCALISED PROSTATE CANCER: RESULTS FROM AN INTERNATIONAL PHASE III RANDOMISED CONTROLLED TRIAL (PACE - A)
PACE-A (phase III) randomised 123 men with localised #ProstateCancer to 5-fraction SBRT☢️ (36.25 Gy) or prostatectomy, without ADT.
➡️At 8 years' median follow-up, biochemical/clinical failure-free rates were 91.2% vs 83.7% (HR 0.48; p=0.18), with 94.8% vs 94.1% at 5 years.
➡️Pad use at 5 years: 8.3% SBRT vs 48% surgery. Grade ≥2 toxicity was low in both arms.
✅SBRT offers comparable long-term cancer control with far better urinary continence.
@nickva1, @alison_tree, @EmmaHall71, @ICR_CTSU, @ICR_London, @royalmarsdenNHS@OncoALert 🚨 #LPCCC27@Silke_Gillessen@AOmlin@ProfKHerrmann@weoncologists
As cancer treatment becomes more complex, new Accela technology is helping expand radiotherapy options with faster, more precise treatment planning and delivery. Learn more about this technology now found at @UHhospitals: ms.spr.ly/6016aYuRk